Rallybio (NASDAQ:RLYB) announced its quarterly earnings results on Thursday. The company reported ($2.80) earnings per share for the quarter, topping the consensus estimate of ($4.31) by $1.51, MarketWatch Earnings reports.
RLYB stock opened at $12.99 on Friday. Rallybio has a 1 year low of $11.86 and a 1 year high of $25.78.
Several research firms have recently issued reports on RLYB. Jefferies Financial Group initiated coverage on shares of Rallybio in a research note on Monday, August 23rd. They set a “buy” rating and a $20.00 target price on the stock. Cowen assumed coverage on Rallybio in a report on Monday, August 23rd. They set an “outperform” rating for the company. Finally, Evercore ISI assumed coverage on Rallybio in a report on Monday, August 23rd. They set an “outperform” rating and a C$40.00 target price for the company.
Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.
Featured Story: Commodities
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.